title: Therapy of pulmonary nocardiosis in immunocompromised mice.
abstract: We compared the bactericidal efficacies of various antimicrobial agents and combinations thereof in experimentally induced Nocardia asteroides pneumonia in immunocompromised mice. Cortisone acetate treatment, which produced impaired cell-mediated immune function, was followed by nasal inoculation of 5 x 10(4) CFU of N. asteroides into each mouse. Therapy was begun 24 h after inoculation and continued for the next 96 h. Dosages of antimicrobial agents resulted in concentrations approximating levels in human serum. Animals from each of nine treatment groups were sacrificed every 24 h. The pulmonary tissue obtained was homogenized and quantitatively cultured. Results were calculated to indicate the number of CFU per gram of lung tissue. Amikacin and imipenem were the two most effective single agents studied. Sulfadiazine and ciprofloxacin were ineffective, and ceftriaxone reduced bacterial counts modestly. Combination therapy did not enhance the bactericidal activities of the agents tested. We conclude that amikacin and imipenem, as well as select broad-spectrum cephalosporins, represent therapy superior to the sulfonamides in this experimental model and may represent alternative treatment for patients who cannot tolerate sulfa agents (e.g., human immunodeficiency virus-infected patients) or who fail primary treatment.
authors.affiliation: Department of Medicine, State University of New York Health Science Center, Brooklyn.
authors.forename: M E
authors.initials: ME
authors.lastname: Gombert
authors.forename: L B
authors.initials: LB
authors.lastname: Berkowitz
authors.forename: T M
authors.initials: TM
authors.lastname: Aulicino
authors.forename: L
authors.initials: L
authors.lastname: duBouchet
mesh_terms: D000583:Amikacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000493:pharmacokinetics / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D003348:Cortisone / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics / Q000627:therapeutic use; D007111:Immunity, Cellular / Q000187:drug effects; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D008171:Lung Diseases / Q000188:drug therapy*; D051379:Mice; D009617:Nocardia Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D009616:Nocardia asteroides; D013411:Sulfadiazine / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013411:Sulfadiazine; D002939:Ciprofloxacin; D015378:Imipenem; D002443:Ceftriaxone; D000583:Amikacin; D003348:Cortisone